Transient receptor potential vanilloid 1 (TRPV1) agonists that bind to the vanilloid pocket are being actively studied in the pharmaceutical industry to develop novel treatments for chronic pain and cancer. To discover synthetic vanilloids without the side effect of capsaicin, a time-consuming process of drug candidate selection is essential to a myriad of chemical compounds. Herein, we propose a novel approach to field-effect transistors for the fast and facile screening of lead vanilloid compounds for the development of TRPV1-targeting medications. The graphene field-effect transistor was fabricated with human TRPV1 receptor protein as the bioprobe, and various analyses (SEM, Raman, and FT-IR) were utilized to verify successful manufacture. Simulations of TRPV1 with capsaicin, olvanil, and arvanil were conducted using AutoDock Vina/PyMOL to confirm the binding affinity. The interaction of the ligands with TRPV1 was detected via the fabricated platform, and the collected responses corresponded to the simulation analysis.
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Global Year
- Pain Management, Research and Education in Low- and Middle-Income Settings
- Sex and Gender Disparities in Pain
- Integrative Pain Care
- Translating Pain Knowledge to Practice
- Back Pain
- Prevention of Pain
- Pain in the Most Vulnerable
- Pain Education
- Joint Pain
- Pain After Surgery
- Global Year Campaign Archives
- My Letter to Pain
- IASP Statements
- ICD-11 Pain Classification
- Global Alliance of Partners for Pain Advocacy (GAPPA)
- National, Regional, and Global Pain Initiatives
- International Pain Summit
- Pain Awareness Month
- Global Year
- Careers
- About
- For Pain Patients and Professionals